To report a case of 3M syndrome following anti-PD-1 therapy in a patient with cervical cancer and to provide guidance on monitoring and management strategies, including specific recommendations for clinicians.
Key Findings:
The patient experienced early neuromuscular symptoms including ptosis and facial weakness, which are critical warning signs.
She developed acute heart failure and atrial fibrillation, with a significant decline in left ventricular ejection fraction from 57% to 40%.
Despite treatment, the patient succumbed to respiratory failure, highlighting the severity of the condition.
Interpretation:
The case highlights the rapid progression of 3M syndrome and underscores the necessity for proactive monitoring of neuromuscular symptoms in patients receiving ICIs to prevent severe outcomes.
Limitations:
The case report is based on a single patient, limiting generalizability and the ability to draw broader conclusions.
Early symptoms of 3M syndrome can be nonspecific and easily misattributed, complicating timely diagnosis and intervention.
Conclusion:
A systematic approach for monitoring and immediate treatment is essential for managing the life-threatening complications associated with immune checkpoint inhibitors, emphasizing the need for early detection and intervention.
